On September 7, 2026, Pee Safe founder Vikas Bagaria told BW Retail World and ETRetail that the Indian intimate-hygiene company is targeting ₹250-300 crore in FY27 revenue — up from ₹130 crore in FY26 — while keeping a public listing on the table for FY29-30. "We are actually gunning for an IPO for '29 and '30. That's our long-term plan," Bagaria said, adding that the business is now close to breakeven and expects to be profitable this fiscal year: "This year, above Rs 200 crore will definitely be on a profitable side."

Why It Matters

Intimate hygiene is the least glamorous corner of sexual wellness and quietly one of the most instructive. Pee Safe's plan is a pure distribution thesis — get to 100,000 doors, then use that shelf as a launch rail for higher-margin adjacent categories — and the Within launch is the test of whether an intimate-care brand can convert topical trust into ingestible trust. That crossover is exactly the beauty/supplement/intimate-wellness convergence that SPINS and LELO survey data have been flagging in the US market all year, running here through Indian pharmacy retail instead of DTC. The IPO signal matters for the wider category. A sexual and intimate wellness company publicly guiding toward a listing — with a PE majority holder and a stated path to profitability — gives the sector something it has almost never had: a visible exit comparable that isn't an acquisition by a larger novelty conglomerate. Read alongside Nua's $50 million Series C the same day, India now has two credible late-stage women's intimate wellness stories running simultaneously, in a year when Western femtech funding has contracted sharply. For investors mapping the category, the centre of gravity for growth capital in intimate wellness is visibly moving east.

The distribution numbers are the operational story. Pee Safe has grown retail reach from about 55,000 stores at the time of its funding round to 60,000-65,000 currently, and plans to hit 100,000 stores over the next four to six quarters across pharmacies, general trade and modern trade. Bagaria said the business has been growing 60-70% year over year, with recent capital funding hiring, consumer-awareness work, the signing of cricketer Smriti Mandhana as brand ambassador, and a new product line. Company financial filings cited by BW put revenue from operations at roughly ₹82 crore in FY25 with net loss narrowing to about ₹4 crore from ₹13.2 crore in FY24.

That new line is Within, a women's nutraceutical and dietary supplement brand launched September 3, 2026, targeting ₹100 crore in revenue within two to three years. The logic is straightforward cross-sell: "We have around 25 million women who are using Pee Safe. If we can give product made just like what Pee Safe is doing, which you can take inside for every age group rather than a generic, as they say one size fits all," Bagaria said. Distribution runs through existing online and offline channels rather than a separate ecosystem, with plans for a doctor-led community involved in product development and ingredient selection.

On ownership, Bagaria confirmed that healthcare-focused investment firm OrbiMed — which invested roughly $32 million (about ₹290 crore) in January 2026 in a round combining primary capital and secondary share sales — holds a majority stake, while noting that "operationally, we professionals, the founders and the key personnel are taking decisions on a day-to-day basis."

Sources

Update — 2026-09-07

Initial entry — story first created.